June 17th 2025
ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
March 10th 2025"In terms of how I select patients, I really look at the timing of metastatic disease, so whether it's metachronous or synchronous and the volume, and I think at this stage, the data are most robust for the synchronous and high-volume patients," says Dr Louise Kostos.
Nima Sharifi, MD, on the link between HSD3B1 and OS in prostate cancer
February 24th 2025“We hypothesized based on prior work that specifically men with low-volume disease, if they inherit this hyperactive form of HSD3B1, they'll have shorter overall survival. It turns out that that's true,” says Nima Sharifi, MD.
Biomarkers in advanced prostate cancer: Liquid biopsy, ctDNA, and more
February 10th 2025"The management of advanced prostate cancer has evolved significantly, driven in part by the integration of diverse biomarkers that guide treatment decisions from diagnosis through progression," says Nedim Ruhotina, MD.